Stroke: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797443
  • Drug Pipelines
  • 181 pages
  • Datamonitor Healthcare
1 of 3
Due to their extended dosing durations, patients receiving treatment for the secondary prevention of ischemic stroke are the most commercially relevant patient subgroup.

This report addresses the following questions:

How will the approval of andexanet alfa as an antidote for Xarelto impact the drug’s sales?
- Which patient subgroups will have the greatest impact on a drug’s sales in ischemic stroke?
- What are the most important factors influencing physicians’ prescribing trends?
- Which branded treatment for ischemic stroke will have the largest market share in 2024?
- What are the most commonly prescribed therapies for both the acute treatment and secondary prevention of ischemic stroke?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: ISCHEMIC STROKE

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Brilinta (ticagrelor)
- Plavix (clopidogrel)
- Xarelto (rivaroxaban)
- Primary Research Methodology

TREATMENT: ISCHEMIC STROKE

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Current Treatment Options
- Prescribing Trends

EPIDEMIOLOGY: STROKE

- Executive Summary
- Disease Background
- Sources and Methodology.
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: ISCHEMIC STROKE

- Executive Summary
- Product Overview
- Product profile: Activase
- Product profile: Aggrenox
- Product profile: Plavix

PIPELINE: ISCHEMIC STROKE

- Executive Summary
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Product profile (late stage): Ampyra
- Product profile (late stage): Brilinta
- Product profile (late stage): Xarelto
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll